← Home / SELLAS Life Sciences Group, Inc. (SLS)
Stock Analysis
SELLAS Life Sciences Group, Inc. (SLS)
SLS
SLS · Market data
10.01 -2.72%
Track SLS in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when SLS price is:
52W Range Position
61%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-02 14:41 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 10.37. Holding above 6.43 keeps the current thesis intact.
⚖️
✓
Fundamentals
Weak / Insufficient
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
6.43
↗
Break Above
Confirmation improves above resistance.
10.37
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 6.43
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
27
●
Financial Results
HIGH
SLS reports financial results
As of June 30, 2026, SELLAS Life Sciences Group, Inc.
8-K Filing • SEC EDGAR
JUN
25
●
Management / Board
MEDIUM
SLS board and management update
(e) Compensatory Arrangements of Certain Officers On June 24, 2026, SELLAS Life Sciences Group, Inc.
8-K Filing • SEC EDGAR
MAY
12
●
Financial Results
HIGH
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Foll...
8-K Filing • SEC EDGAR
What's Driving SLS?
📈 Technical recovery is improving
Momentum is Neutral. Watch 10.37 for confirmation and 6.43 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 6.43 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
42.0
◎
How to read this setup
The next meaningful technical decision is likely to occur between support at 6.43 and resistance at 10.37. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
SLS — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$1.8B
Company size
EV
$1.7B
Debt-adjusted value
P/B
16.9
Premium
FCF Yield
-1.55%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
0.00
↘ Weak
📈 Net Income
-8.41M
≈ Insufficient
🧮 EPS (Basic)
-0.05
≈ Insufficient
SELLAS Life Sciences Group, Inc.
Related Opportunities